SBIR-STTR Award

Fluorescent Trnas for Real-Time Monitoring of Protein Synthesis in Living Cells
Award last edited on: 4/18/19

Sponsored Program
STTR
Awarding Agency
NIH : NIGMS
Total Award Amount
$200,000
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Barry S Cooperman

Company Information

Anima Cell Metrology Inc

75 Claremont Road Suite 102
Bernardsville, NJ 07924
   (908) 776-6633
   info@animapsl.com
   www.animapsl.com

Research Institution

University of Pennsylvania

Phase I

Contract Number: 1R41GM090404-01A1
Start Date: 9/5/10    Completed: 9/4/11
Phase I year
2010
Phase I Amount
$200,000
As technologies of gene and protein cataloging are maturing, the study of cellular dynamics is becoming the next frontier in biological research. New technologies are required to capture the complexity of cellular dynamics. Against this background we propose the development of a straightforward method to monitor protein synthesis from living cells in real time and subcellular resolution. The method, termed DiP (""Di-Peptide""), transfects cells with tRNAs that are fluorescently-labeled to form FRET pairs. When the cellular protein synthetic machinery is active, such tRNAs will be held (for ~500 milliseconds) in adjacent sites of active ribosomes, generating FRET signals, the intensity of which should, under normal conditions of cell growth and development, correlate with the rate of protein synthesis in the cell. DiP technology can measure either overall rates of protein synthesis (Overall DiP), by employing bulk labeled tRNAs, or rates of synthesis of selected proteins of interest (Specific DiP), by using specific labeled tRNAs.In both cases, high temporal resolution and subcellular localization are easily achieved. Such capabilities have many valuable applications in areas ranging from basic research, to clinical trials, to the manufacture of biotherapeutics. Over the last year we have successfully employed Overall DiP to generate FRET signals in several mammalian cell lines. Our most important tasks in advancing DiP development in Phase 1 of this project are to demonstrate that 1) synthesis rates of specific proteins can be monitored by Specific DiP;2) DiP assays can be calibrated to provide quantitative measurements;and 3) such assays can provide useful information in a variety of scientific and pharmaceutical applications. To accomplish these tasks we will prepare amino acid-specific fluorescently labeled tRNAs and use them to determine the correlation between in vivo FRET intensity and protein expression for two selected mammalian proteins. In addition, methodology, reagents, algorithms and software will be developed to estimate the concentration of active ribosomes;procedures will be implemented to differentiate FRET signals arising from active ribosomes from those arising from frozen ribosomes;and feasibility studies using Overall DiP will be conducted to measure the expression of a number of disease-related proteins. In Phase 2 we plan to develop further the spectrum of applications of DiP, building on the knowledge gained through phase 1 work and to commercialize DiP as a new research tool with wide applicability for the of study protein- synthesis related diseases, and for clone selection and quality control applications in production of therapeutic proteins. , ,

Public Health Relevance:
Many if not most diseases afflicting humankind arise from abnormalities in the biosynthesis of proteins that are found within human cells. Advances in the diagnosis and treatment of such diseases depend in large measure on our ability to monitor changes in protein synthesis when and where they occur. We are proposing the development of a straightforward method to monitor protein synthesis from living cells in real time and at sub-cellular resolution that should have wide applicability for the elucidation and treatment of protein-synthesis related diseases.

Thesaurus Terms:
Active Sites;Algorithms;Amino Acids;Area;Assay;Astrocytes;Astrocytus;Astroglia;Basic Research;Basic Science;Bioassay;Biologic Assays;Biologic Therapy;Biological Assay;Biological Response Modifier Therapy;Biological Therapy;Body Tissues;Bovine Species;Budgets;California;Cataloging;Catalogs;Cattle;Cell Communication And Signaling;Cell Line;Cell Lines, Strains;Cell Signaling;Cellline;Cells;Cellular Expansion;Cellular Growth;Clinical Trials;Clinical Trials, Unspecified;Collaborations;Collagen Type I;Coloring Agents;Computer Programs;Computer Software;Cy5;Cysteine-Specific Trna;Detection;Development;Diagnosis;Disease;Disorder;Dyes;Eukaryote;Eukaryotic Cell;Fret;Feasibility Studies;Fluorescence Resonance Energy Transfer;Forecast Of Outcome;Freezing;Gel;Gene Proteins;Glycine-Specific Trna;Growth And Development;Growth And Development Function;Hela;Hela Cells;Human;Human, General;Intracellular Communication And Signaling;Knowledge;Label;Laboratories;Libraries;Life;Liver;Liver Fibrosis;Lysine-Specific Trna;Mammalian Cell;Mammals, Mice;Man (Taxonomy);Man, Modern;Mass Spectrum;Mass Spectrum Analysis;Measurement;Measures;Mesenchymal Progenitor Cell;Mesenchymal Stem Cells;Messenger Rna;Method Loinc Axis 6;Methodology;Methods;Methods And Techniques;Methods, Other;Mice;Monitor;Msec;Multiple Myeloma;Murine;Mus;Myeloma, Plasma-Cell;Peptide Biosynthesis, Ribosomal;Peptides;Pharmaceutical Agent;Pharmaceuticals;Pharmacologic Substance;Pharmacological Substance;Phase;Phenylalanine-Specific Trna;Photometry/Spectrum Analysis, Mass;Preparation;Procedures;Production;Prognosis;Proline-Specific Trna;Protein Biosynthesis;Protein Biosynthesis, Ribosomal;Protein Gene Products;Protein Synthesis, Ribosomal;Proteins;Proteomics;Quality Control;Rna, Messenger;Rna, Transfer, Cys;Rna, Transfer, Gly;Rna, Transfer, Lys;Rna, Transfer, Phe;Rna, Transfer, Pro;Reagent;Research;Resolution;Rhodamine;Rhodamines;Ribonucleic Acids, Transfer;Ribosomes;S Cerevisiae;Saccharomyces Cerevisiae;Sampling;Signal Transduction;Signal Transduction Systems;Signaling;Software;Spectrometry, Mass;Spectroscopy, Mass;Spectrum Analyses, Mass;Spectrum Analysis, Mass;Techniques;Technology;Time;Tissues;Transfer Rna;Triplet Codon-Amino Acid Adaptor;Type 1 Collagen;Universities;Viral;Work;Yeast, Baker's;Yeast, Brewer's;Aminoacid;Base;Beta-Defensins;Biological Research;Biological Signal Transduction;Biotherapeutics;Biotherapy;Body System, Hepatic;Bovid;Bovine;Burden Of Disease;Burden Of Illness;Cell Growth;Clinical Diagnosis;Clinical Investigation;Combinatorial;Commercialization;Computer Program/Software;Computerized Data Processing;Cow;Cultured Cell Line;Cyanine Dye 5;Data Processing;Disease Burden;Disease/Disorder;Eukaryotida;Frontier;Gene Product;Hepatic Fibrosis;In Vivo;Interest;Mrna;Millisecond;Myeloma;Myelomatosis;New Technology;Organ System, Hepatic;Outcome Forecast;Prevent;Preventing;Protein Expression;Protein Synthesis;Public Health Relevance;Response;Signal Processing;Synthetic Protein;Trna;Trna(Cys);Trna(Gly);Trna(Lys);Trna(Phe);Trna(Pro);Trnacys;Trnagly;Trnalys;Trnaphe;Trnapro;Therapeutic Protein;Tool;Years Of Life Lost To Disability;Years Of Life Lost To Disease

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----